However, such evidence falls short of associating the terminal Hippo pathway effectors YAP and TAZ to a functional role in CD8 cells, and the therapeutic potential for targeting these factors in the cancer setting remains incompletely explored. The gene discussed is CD8A; the disease is cancer.